0001520138-20-000056.txt : 20200213 0001520138-20-000056.hdr.sgml : 20200213 20200213173008 ACCESSION NUMBER: 0001520138-20-000056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200213 DATE AS OF CHANGE: 20200213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 20612249 BUSINESS ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 BUSINESS PHONE: 310-444-4300 MAIL ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20191231_10q.htm FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: December 31, 2019

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 001-39015

BIOVIE INC.

(Exact name of registrant as specified in its charter)

Nevada		46-2510769
(State or other jurisdiction of incorporation or organization)		(I.R.S. Empl. Ident. No.)

2120 Colorado Avenue Suite 230

Santa Monica, CA 90404

(Address of principal executive offices, Zip Code)

(310)-444-4300

(Registrant's telephone number, including area code)

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

There were 5,194,924 shares of the Registrant’s $0.0001 par value Class A common stock outstanding as of February 5, 2020.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
	Condensed Balance Sheets at December 31, 2019 (unaudited) and June 30, 2019	1
	Condensed Statements of Operations (unaudited) - for the three months and six months ended December 31, 2019 and 2018	2
	Condensed Statements of Cash Flows (unaudited) - for the six months ended December 31, 2019 and 2018	3
	Condensed Statements of Changes in Stockholders’ (Deficit) Equity (unaudited) - for the periods July 1, 2018 through December 31, 2018 and July 1, 2019 through December 31, 2019	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	22

SIGNATURES		23

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

BioVie Inc.

Condensed Balance Sheets

	December 31,			June 30,
	2019			2019
ASSETS	(Unaudited)

CURRENT ASSETS:
Cash	$	3,108		$	339,923
Other assets		550,810			334,150
Total current assets		553,918			674,073

OTHER ASSETS:
Intangible assets, net		1,439,915			1,554,603
Goodwill		345,711			345,711
Total other assets		1,785,626			1,900,314

TOTAL ASSETS	$	2,339,544		$	2,574,387

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	1,085,177		$	443,480
Derivative liability - warrants		2,674,000			—
Derivative liability - conversion option on convertible debenture		573,200			—
Loan payable - related party		30,000
Convertible debenture - related party, net of discount $478,405 and $0 at December 31, 2019 and 2018, respectively		21,595			—
Total current liabilities		4,383,972			443,480

Commitments and contingencies (Note 8)

STOCKHOLDERS' (DEFICIT) EQUITY

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2019 and June 30, 2019, respectively; 5,183,724 and 4,058,724 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively		518			406
Additional paid in capital		19,472,373			9,392,573
Accumulated deficit		(21,517,319	)		(7,262,072	)
Total stockholders' (deficit) equity		(2,044,428	)		2,130,907

TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	$	2,339,544		$	2,574,387

See accompanying notes to unaudited condensed financial statements

-1-

Table of Contents

BioVie Inc.

Condensed Statements of Operations

(Unaudited)

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	December 31 2019			December 31, 2018			December 31 2019			December 31 2018

OPERATING EXPENSES:
Amortization		57,344		$	57,344			114,689		$	114,689
Research and development expenses		346,514			206,019			688,015			400,540
Selling, general and administrative expenses		306,589			237,507			613,961			477,069
TOTAL OPERATING EXPENSES		710,447			500,870			1,416,665			992,298

LOSS FROM OPERATIONS		(710,447	)		(500,870	)		(1,416,665	)		(992,298	)

OTHER (INCOME) EXPENSE :
Change in fair value of derivative liabilities		(7,396,192	)		—			(7,758,778	)		—
Gain on settlement of debt		—			—			—			(51,400	)
Interest expense		20,920			—			3,498,535			271
Interest income		(213	)		(360	)		(233	)		(788	)
TOTAL OTHER (INCOME) EXPENSE, NET		(7,375,485	)		(360	)		(4,260,476	)		(51,917	)


NET INCOME (LOSS)	$	6,665,038		$	(500,510	)	$	2,843,811		$	(940,381	)

Deemed dividends for commitment shares and rachet adjustments		—			—			17,099,058			48,659

NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	6,665,038		$	(500,510	)	$	(14,255,247	)	$	(989,040	)

NET INCOME (LOSS) PER COMMON SHARE
- Basic	$	1.29		$	(0.20	)	$	(3.06	)	$	(0.40	)
- Diluted	$	1.29		$	(0.20	)	$	(3.06	)	$	(0.40	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
- Basic		5,183,724			2,520,429			4,661,183			2,497,457
- Diluted		5,183,724			2,520,429			4,661,183			2,497,457

See accompanying notes to unaudited condensed financial statements

-2-

Table of Contents

BioVie Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Six Months Ended			Six Months Ended
	December 31, 2019			December 31, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	2,843,811		$	(940,381	)
Adjustments to reconcile net loss to net cash to cash used in operating activities:
Amortization of intangible assets		114,689			114,689
Stock based compensation expense		11,162			19,697
Gain on settlement of debt		—			51,400
Interest expense from convertible debenture		3,497,264			—
Change in fair value of derivative liabilities		(7,758,778	)		—
Changes in operating assets and liabilities
Other assets		(216,660	)		—
Accounts payable and accrued expenses		641,697			(456,422	)
Net cash used in operating activities		(866,815	)		(1,211,017	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt		—			(244,300	)
Proceeds from issuance of preferred shares		—			3,040,000
Proceeds from loan payable - related party		30,000
Proceeds from convertible debenture - related party		500,000			—
Net cash provided by financing activities		530,000			2,795,700

Net (decrease) increase in cash		(336,815	)		1,584,683

Cash, beginning of period		339,923			45,800

Cash, end of period	$	3,108		$	1,630,483

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	1,272		$	—
Cash paid for taxes	$	—		$	—

SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Conversion of preferred shares to common stock	$	—		$	3,200,000
Settlement of debt by issuance of common stock and forgiveness of debt	$	—		$	1,150,135
Cashless exercise of warrants	$	—		$	224
Deemed dividends for ratchet adjustments to warrants	$	—		$	48,659
Deemed dividends for commitment shares	$	17,099,058			—
Stock warrants classified as derivative liability	$	7,530,308			—

See accompanying notes to unaudited condensed financial statements

-3-

Table of Contents

BioVie Inc.

Condensed Statements of Changes in Stockholders’ (Deficit) Equity

For the periods July 1, 2018 through December 31, 2018 and July 1, 2019 through December 31, 2019

(Unaudited)

																	Total
											Additional						Stockholders’
	Preferred Stock						Common Stock				Paid in			Accumulated			Equity
	Shares			Amount			Shares		Amount		Capital			Deficit			(Deficit)

Balance, June 30, 2018		—		$	—			788,026	$	79	$	4,880,246		$	(4,769,126	)	$	111,199

Issuance of preferred stock in a private placement		2,133,332			3,200,000			—		—		3,200,000			—			3,200,000

Conversion of preferred stock to common stock		(2,133,332	)		(3,200,000	)		1,706,666		171		(171	)		—			—

Issuance of shares in exchange for debt settlement		—			—			7,804		1		1,150,134			—			1,150,135

Stock option compensation		—			—			—		—		3,412			—			3,412

Cashless exercise of warrants		—			—			17,935		2		(2	)		—			—

Deemed dividends for ratchet adjustment to warrants		—			—			—		—		48,659			(48,659	)		—

Net loss for the three months ended September 30, 2018		—			—			—		—		—			(439,871	)		(439,871	)

Balance, September 30, 2018		—			—			2,520,431		253		9,282,278			(5,257,656	)		4,024,875

Stock option compensation		—			—			—		—		16,285			—			16,285

Net loss for the three months ended December 31, 2018		—			—			—		—		—			(500,510	)		(500,510	)

Balance, December 31, 2018		—		$	—			2,520,431	$	253	$	9,298,563		$	(5,758,166	)	$	3,540,650



Balance June 30, 2019		—		$	—			4,058,724		406		9,392,573		$	(7,262,072	)	$	2,130,907

Issuance of commitment shares		—			—			1,125,000		112		10,068,638			—			10,068,750

Deemed dividend for commitment shares		—			—			—		—		—			(17,099,058	)		(17,099,058	)

Net loss for the three months ended September 30, 2019		—			—			—		—		—			(3,821,227	)		(3,821,227	)

Balance, September 30, 2019		—			—			5,183,724		518		19,461,211			(28,182,357	)		(8,720,628	)

Stock option compensation		—			—			—		—		11,162			—		$	11,162

Net income for the three months ended December 31, 2019		—			—			—		—		—			6,665,038			6,665,038

Balance, December 31, 2019		—		$	—			5,183,724	$	518	$	19,472,373		$	(21,517,319	)	$	(2,044,428	)

See accompanying notes to unaudited condensed financial statements

-4-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

1.	Background Information

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017. In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general agreement with the Company’s proposed randomized and controlled study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design. In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

-5-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

2.	Liquidity and Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company had an accumulated deficit of approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of December 31, 2019. In December 2019, Acuitas provided the Company, a short-term interest free advance of $30,000. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b/3 clinical trial until sufficient funding is secured.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected the reverse stock split of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-6-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

3.	Significant Accounting Policies

Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net income (loss) per Common Share

Basic net income (loss) per common share is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding during the period.

Diluted net income (loss) per common share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December 31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018:

	December 31, 2019		December 31, 2018
	Number of Shares		Number of Shares
Stock Options		60,400		44,400
Warrants		1,374,667		1,731,525
Total		1,435,067		1,775,925

-7-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

3.	Significant Accounting Policies (continued)

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

4.	Intangible Assets

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:

	December 31, 2019			June 30, 2019

Intellectual Property	$	2,293,770		$	2,293,770
Less Accumulated Amortization		(853,855	)		(739,167	)
Intellectual Property, Net	$	1,439,915		$	1,554,603

Amortization expense for the three-month period ended December 31, 2019 and 2018 was $57,344 and $57,344 respectively Amortization expense for the six-month period ended December 31, 2019 and 2018 was $114,689 and $114,689 respectively.

Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining six months)	$ 114,689
2021	229,377
2022	229,377
2023	229,377
2024	229,377
2025	229,377
Thereafter	178,341
	$ 1,439,915

-8-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

5.	Related Party Transactions

Equity Transactions with Acuitas

On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holding, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us.

Each share of Preferred Stock automatically converted into 100 shares of common stock (prior to reverse split) upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock;

-9-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

5.	Related Party Transactions (continued)

Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;

Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

Convertible Debenture Transaction with Acuitas

On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the “Debenture”) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.

The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended December 31, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $21,595 for the six-month period ended December 31, 2019.

The Company received partial draws of draw number two of the Debenture of $25,000 and $5,000 on December 5, 2019 and December 13,2019 respectively. Acuitas and the Company continue to discuss the need and timing for some or all of the remaining draws under the Agreement. (See subsequent events).

-10-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

5.	Related Party Transactions (continued)

Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

-11-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

6.	Fair Value Measurements

At December 31, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

	Fair Value Measurements at
	December 31, 2019
	Level 1		Level 2		Level 3		Total

Derivative liability - Warrants	$	—	$	—	$	2,674,000	$	2,674,000
Derivative liability -Conversion option on convertible debenture		—		—		573,200		573,200
Total derivatives	$	—	$	—	$	3,247,200	$	3,247,200

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2019:

	Derivative liabilities - Warrants			Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019	$	—		$	—
Additions to level 3 liabilities		8,367,012			2,638,966
Change in in fair value of level 3 liability		(257,288	)		(105,298	)
Transfer in and/or out of Level 3		—			—
Balance at September 30, 2019		8,109,724			2,533,668
Additions to level 3 liabilities		—			—
Change in in fair value of level 3 liability		(5,435,724	)		(1,960,468	)
Transfer in and/or out of Level 3		—			—
Balance at December 31, 2019	$	2,674,000		$	573,200

Derivative liability – Warrants

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise.

-12-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

6.	Fair Value Measurements (continued)

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions: stock price of $8.95, exercise price of $4.00, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of 0%, and risk-free interest rate of 1.52%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50, exercise price of $4.00, term of 5 year expiring September 2024, volatility of 80.79%, dividend yield of 0%, and risk-free interest rate of 1.69%. (See note 5 “Related Party Transactions – Convertible debenture transactions”)

Derivative liability – Conversion option in convertible debenture

The Company valued the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. (See note 5 “Related Party Transactions – Convertible debenture transactions with Acuitas” as of September 24, 2019). The conversion option was valued on September 24, 2019 using the Black Scholes-Mertons model with the following assumptions: stock price of $8.95, conversion price of $4.00, term of 1 year expiring September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50, conversion price of $4.00, term of 1 year expiring September 2020, volatility of 109.83%, dividend yield of 0%, and risk-free interest rate of 1.59%.

7.	Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2019:

	Options		Weighted-Average Exercise Price		Weighted Remaining Average Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2019		58,000	$	12.50		5.2	$	87,480
Granted		2,400		7.42		4.1		—
Options Exercised or Forfeited		—		—		—		—
Outstanding at December 31, 2019		60,400	$	12.29		4.5	$	2,100
Exercisable at December 31, 2019		60,400	$	12.29		4.5	$	2,100

-13-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

7.	Equity Transactions (continued)

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019:

	December 31 2019			December 31 2018
Expected life of options (In years)		5			5
Expected volatility		71.55	%		67.91	%
Risk free interest rate		1.61	%		2.98	%
Dividend Yield		0	%		0	%

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $0 and $11,162 for the three- and six- month periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended December 31, 2018, respectively.

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2019:

Exercise Price		Outstanding		Weighted Average Contract Life		Exercisable
$	3.75		5,600		4.1		5,600
$	6.25		11,200		4.2		11,200
$	7.50		25,600		6.2		25,600
$	8.75		1,600		4.3		1,600
$	12.50		4,000		3.1		4,000
$	25.00		1,600		2.8		1,600
$	26.25		4,400		2.3		4,400
$	27.50		800		2.2		800
$	28.75		1,600		2.6		1,600
$	31.25		4,000		1.9		4,000

Stock Warrants

The following table summarizes the warrants activity during the six months ended December 31, 2019:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)		Aggregate Intrinsic Value
Outstanding and exercisable at June 30, 2019		124,667	$	45.00		5.6	$	716,653
Granted		1,250,000	$	4.00		4.7	$	—
Expired		—	$	—		—	$	—
Outstanding and exercisable at December 31, 2019		1,374,667	$	7.72		4.7	$	139,498

Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,455 expire in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending June 30, 2025.

-14-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

7.	Equity Transactions (continued)

Offerings of Common Stock and Warrants

Issuance of Stock Options

On October 1, 2019, the Company issued stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 13, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $7.50 at any time from date of issuance and expire in 5 years from the date of issuance.

On November 10, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.

8.	Commitments and Contingencies

Office Lease

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country.

-15-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Six Months Ended December 31, 2019 and 2018

(unaudited)

8.	Commitments and Contingencies (continued)

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally the Company obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy).

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

9.	Subsequent Events

On January 2, 2020, the Company issued 11,200 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $3.50.

On January 3, 2020, the Company received a third partial draw of $20,000 and on January 14, 2020 a fourth partial draw of $250,000 of draw number two of the Debenture. The total of the partial draw received under draw number two of the Debenture was $300,000 at February 12, 2020. Acuitas and the Company continue to discuss the need and timing for some or all the remaining draws under the Debenture Agreement.

On February 11, 2020, the Company entered into a letter agreement dated February 10, 2020 with Acuitas regarding Acuitas’ previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company’s intellectual property rights and commitment to purchase such securities upon the closing of the Company’s planned public offering (the “Public Offering”) of shares of Class A common stock (the “Common Stock”) as described in its Registration Statement on Form S-1 (File No. 333-231136) and commitment to purchase such additional securities would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company’s current bridge financing with Acuitas were to be made based with respect to the Company’s ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith.

-16-

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales, expenses and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

Management’s Discussion

BioVie is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies targeting life-threatening complications of liver cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times more worldwide. Our therapeutic drug candidate BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

-17-

Table of Contents

Comparison of the three months ended December 31, 2019 to the three months ended December 31, 2018

Net income (loss)

The net income for the three months ended December 31, 2019 was $6.7 million as compared to a net loss of $501,000 for the three months ended December 31, 2018. The increase in net income (loss) of $7.2 million was due to a decrease in fair value of derivative liabilities of approximately $7.4 million offset by an increase in operating expenses of approximately $210,000. The change in the fair value of derivative liabilities was due to a decrease in the Company’s stock price.

Total operating expenses for the three months ended December 31, 2019 were approximately $710,000 compared to $501,000 for the three months ended December 31, 2018. The net increase of approximately $209,000 was primarily due to activities related to the Phase 2a clinical trials wrap up and preparation of the protocols for the Phase 2b/3 trials during the three months ended December 31, 2019 and an increase in selling, general and administrative expenses.

Research and Development Expenses

Research and development expenses were approximately $347,000 for the three months ended December 31, 2019, an increase of $141,000, from $206,000 for the three months ended December 31, 2018. The increase was primarily attributed to the wrapping up of the phase 2a clinical trials and readying for the next phase of trials including the preparing the protocols and manufacturing of the prefilled syringe which may be used in the next phase of trials subject to FDA clearance.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $307,000 for the three months ended December 31, 2019, a net increase of approximately $69,000, from $238,000 for the three months ended December 31, 2018. The net increase was primarily attributed to an increase in the insurance premiums of approximately $73,000 for increased coverage.

Comparison of the six months ended December 31, 2019 to the six months ended December 31, 2018

Net income (loss)

The net income for the six months ended December 31, 2019 was $2.8 million as compared to a net loss of $940,000 for the six months ended December 31, 2018. The increase in net income of $3.8 million was due to a decrease in fair value of derivative liabilities of $7.8 million offset by an increase in operating expenses of $424,000 and increase in interest expense of $3.5 million related to the embedded derivative liability warrants. The change in the fair value of derivative liabilities was due to a decrease in the Company’s stock price.

Total operating expenses for the six months ended December 31, 2019 were approximately $1.4 million compared to $992,000 for the six months ended December 31, 2018. The net increase of approximately $424,000 was primarily due to activities related to the Phase 2a clinical trials wrap up and preparation of the protocols for the Phase 2b/3 trials during the six months ended December 31, 2019 and an increase in selling, general and administrative expenses.

Research and Development Expenses

Research and development expenses were approximately $688,000 for the six months ended December 31, 2019, an increase of $287,000, from $401,000 for the six months ended December 31, 2018. The increase was primarily attributed to the wrapping up of the phase 2a clinical trials and readying for the next phase of trials including the preparing the protocols and manufacturing of the prefilled syringe which may be used in the next phase of trials subject to FDA clearance.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $614,000 for the six months ended December 31, 2019, a net increase of approximately $137,000, from $477,000 for the six months ended December 31, 2018. The net increase was primarily attributed to an increase in the insurance premiums of approximately $88,000 for increased coverage, increased payroll of approximately $30,000 due the hiring of a half time chief financial officer that joined in October 2018 and other expenses of approximately $19,000 related to activities of the Company’s capital raise and up listing to the Nasdaq.

-18-

Table of Contents

Capital Resources and Liquidity

At December 31, 2019 the Company had approximately $3,000 in cash and had completed its Phase 2a clinical trial of the BIV201 therapy. On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $750,000 has been drawn to date. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under discussion with Acuitas in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured. On January 3, 2020, Acuitas provided the Company a short-term interest free advance of $20,000. The short-term advance along with the $30,000 advances in December 2019 were rolled into the partial draw number 2 of $250,000 received on January 14, 2020.

As of December 31, 2019, the Company had an accumulated deficit of approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of sufficient financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected a reverse stock split of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.

Management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

These circumstances raise substantial doubt on our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

-19-

Table of Contents

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies and Estimates

For the six-month period ended December 31, 2019, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2019.

New Accounting Pronouncements

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

Item 4. Controls and Procedures

We maintain “disclosure controls and procedures.” Such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also are based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act), that occurred during the quarter ended December 31, 2019 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

-20-

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

Item 2. Unregistered sales of equity securities

All sales of unregistered securities during the six months ended December 31, 2019 were previously disclosed in a Current report on Form 8-K.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

Director Hari Kumar resigned from the Company’s Board of Directors effective February 12, 2020. Dr. Kumar had served as a director since May 2017. The Company appreciates the dedicated service of Dr. Kumar.

-21-

Table of Contents

Item 6. Exhibits

(a) Exhibit index

Exhibit

10.1*		BioVie, Inc. Letter Agreement with Acuitas Group Holdings, LLC dated as of February 10, 2020
31.1*		Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*		Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1**		Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

*	Filed herewith.

**	Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

-22-

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioVie Inc.,


Signature	Titles	Date

/s/ Terren Peizer ________________ Terren Peizer	Chairman and Chief Executive Officer (Principal Executive Officer)	February 13, 2020
/s/ Joanne Wendy Kim _________________ Joanne Wendy Kim	Chief Financial Officer (Principal Financial and Accounting Officer)	February 13, 2020

-23-

EX-10.1 2 bivi-20191231_10qex10z1.htm EXHIBIT 10.1

Exhibit 10.1

February 10, 2020

Acuitas Group Holdings, LLC

2120 Colorado Ave.

Suite 230

Santa Monica, CA 90404

Attention: Terren Peizer

Dear Mr. Peizer:

Reference is hereby made to the following documents: (i) that certain Securities Purchase Agreement, dated July 3, 2018, by and among BioVie Inc., a Nevada corporation (“BioVie”), Acuitas Group Holdings, LLC (“Acuitas”), and the other purchasers identified on the signature pages thereto (the “Initial Securities Purchase Agreement”), (ii) that certain letter agreement dated June 24, 2019 between BioVie and Acuitas (the “Letter Agreement”), and (iv) that certain Securities Purchase Agreement, dated September 24, 2019 between BioVie and Acuitas (the “Bridge Securities Purchase Agreement”). All capitalized terms used herein without definition shall have the same meanings herein as such terms have in the Original Securities Purchase Agreement or the Bridge Securities Purchase Agreement, as applicable.

The purpose of this letter agreement (this “Extension Agreement”) is to confirm the continued effectiveness of certain conditional waivers under the Original Securities Purchase Agreement and extend the period during which such conditional waivers may be satisfied by BioVie. The Board of Directors, based upon the findings and recommendations of the Capital Structure Committee of the Board of Directors, has determined that such extension is in the best interest of BioVie and its stockholders and will facilitate the ability of BioVie to raise capital. The parties also seek to clarify the requirements of the 10% OID Convertible Delayed Draw Debenture attached as Exhibit B to the Bridge Securities Purchase Agreement (the “Debenture”) to better reflect the parties’ intentions regarding ongoing draws under the Debenture in light of current capital requirements of the Company and market conditions.

In consideration of the foregoing, the covenants and agreements herein contained, other valuable consideration (the receipt of which is hereby acknowledged) and intending to be legally bound hereby, BioVie and Acuitas hereby agree as follows:

1. Extension. In consideration of the continued mutual efforts of Acuitas and BioVie to raise external capital, each of Acuitas and BioVie hereby agree that (i) all references in Section 2(a) of the Letter Agreement to “November 30, 2019” shall be modified to refer to “April 30, 2020” and (ii) the dates set forth in the definition “Availability Period” in the Debenture reflect the expectations of the parties as of entering into the Bridge Securities Purchase Agreement and that the passing of such dates or failure to fully exercise any draw rights thereunder by such dates shall not give rise to any claims prior to any such formal draws in accordance with the Debenture. Each of Acuitas and BioVie hereby irrevocably and unconditionally waives any and all rights or duties which may have arisen under the Letter Agreement and the Bridge Securities Purchase Agreement from and after November 30, 2019 to the date hereof,

solely as a result of such deadline having been exceeded or such draw dates having been passed and BioVie withdraws that portion of the second draw under the Debenture which shall not have been satisfied prior to the date hereof, subject to redraw in accordance with the foregoing understanding.

2. Confirmation of Post Reverse Split Share Determinations.

(a) Each of Acuitas and BioVie hereby agree that as provided in the Letter Agreement and modified by the Bridge Securities Purchase Agreement, the amount of Transaction Shares referred to in the Letter Agreement, after giving effect to BioVie’s 1:125 reverse split, shall equal 5,359,832.

3. Representations and Warranties of BioVie. BioVie hereby represents and warrants as follows:

(a) BioVie has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Letter Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Letter Agreement by BioVie and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of BioVie and no further action is required by BioVie, the Board of Directors or BioVie’s shareholders in connection herewith other than in connection with the Required Approvals. This Letter Agreement has been (or upon delivery will have been) duly executed by BioVie and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of BioVie enforceable against BioVie in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b) The execution, delivery and performance by BioVie of this Letter Agreement, the issuance of the Exchange Shares and the consummation by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of BioVie’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of BioVie or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a BioVie or Subsidiary debt or otherwise) or other understanding to which BioVie or any Subsidiary is a party or by which any property or asset of BioVie or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which BioVie or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of BioVie or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(c) BioVie is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by BioVie of this Letter Agreement, other than: (i) the filing of a Current Report on Form 8-K following the execution of this Letter Agreement, (ii) application(s) to each applicable Trading Market for the listing of the Exchange Shares for trading thereon in the time and manner required thereby, and (iii) such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).

-2-

(d) The Exchange Shares are duly authorized and, when issued in accordance herewith, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by BioVie.

(e) Neither BioVie nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange. Assuming the representations and warranties of Acuitas contained herein are true and complete, the Exchange will qualify for the registration exemption contained in Section 3(a)(9) of the Securities Act.

4. Representations and Warranties of Acuitas. Acuitas hereby represents and warrants as follows:

(a) Acuitas is an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Letter Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Letter Agreement and performance by Acuitas of the transactions contemplated hreby have been duly authorized by all necessary limited liability company or similar action on the part of Acuitas. This Letter Agreement has been duly executed by Acuitas, and when delivered by Acuitas, will constitute the valid and legally binding obligation of Acuitas, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b) Neither Acuitas nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange, and Acuitas will receive no additional consideration for the Warrant other than the Exchange Shares.

5. No Other Amendments or Waivers. Except as expressly set forth herein, this Letter Agreement shall not be deemed to be a waiver, amendment or modification of any provisions of the Securities Purchase Agreement, or of any right, power or remedy of Acuitas or the other Purchasers, or constitute a waiver, amendment or modification of any provision of the Securities Purchase Agreement (except to the extent herein set forth). Except as set forth herein, Acuitas reserves all rights, remedies, powers, or privileges.

6. Conflicts. Except as expressly set forth in this Letter Agreement, the terms and provisions of the Securities Purchase Agreement shall continue unmodified and in full force and effect. In the event of any conflict between this Letter Agreement and the Securities Purchase Agreement, this Letter Agreement shall control.

7. Governing Law; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Letter Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Letter Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of

-3-

New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Letter Agreement), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Letter Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of this Letter Agreement, then the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY EITHER PARTY AGAINST THE OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

8. Notices; Miscellaneous. Section 5.4 (Notices) of the Original Securities Purchase Agreement shall govern any and all notices or other communications or deliveries required or permitted to be provided hereunder. Sections 5.6 (Headings), 5.12 (Severability), 5.15 (Remedies), and 5.19 (Construction) of the Original Securities Purchase Agreement are incorporated herein, with each reference to the “Agreement” or the “Transaction Documents” therein being replaced by a reference to this Letter Agreement.

9. Execution. This Letter Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

(Signature Pages Follow)

-4-

Kindly acknowledge your acceptance of this Letter Agreement by executing in the space provided below.

Sincerely,

BIOVIE INC.

By:/s/ Jonathan Adams

Name: Jonathan Adams

Title: President and Chief Operating Officer

Acknowledged and agreed:

ACUITAS GROUP HOLDINGS, LLC

By:/s/ Terren S. Peizer

Name: Terren S. Peizer

Title: Managing Member

-5-

EX-31.1 3 bivi-20191231_10qex31z1.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Terren Peizer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 13, 2020

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-31.2 4 bivi-20191231_10qex31z2.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Joanne Wendy Kim, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 13, 2020

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 5 bivi-20191231_10qex32z1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Terren Peizer, Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 13, 2020

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-32.2 6 bivi-20191231_10qex32z2.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 13, 2020

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.INS 8 bivi-20191231.xml XBRL INSTANCE FILE 0001580149 2020-02-05 0001580149 2019-07-01 2019-12-31 0001580149 2019-12-31 0001580149 us-gaap:CommonStockMember 2019-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001580149 us-gaap:RetainedEarningsMember 2019-06-30 0001580149 us-gaap:StockOptionMember 2019-06-30 0001580149 bivi:StockOptionOneMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionOneMember 2019-12-31 0001580149 bivi:StockOptionTwoMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionTwoMember 2019-12-31 0001580149 bivi:StockOptionThreeMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionThreeMember 2019-12-31 0001580149 bivi:StockOptionFourMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionFourMember 2019-12-31 0001580149 bivi:StockOptionFiveMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionFiveMember 2019-12-31 0001580149 bivi:StockOptionSixMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionSixMember 2019-12-31 0001580149 bivi:StockOptionSevenMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionSevenMember 2019-12-31 0001580149 us-gaap:CommonStockMember 2019-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-12-31 0001580149 us-gaap:WarrantMember 2019-07-01 2019-12-31 0001580149 us-gaap:StockOptionMember 2019-07-01 2019-12-31 0001580149 us-gaap:StockOptionMember 2019-12-31 0001580149 2018-07-01 2018-12-31 0001580149 bivi:StockOptionEightMember 2019-12-31 0001580149 bivi:StockOptionEightMember 2019-07-01 2019-12-31 0001580149 bivi:StockOptionNineMember 2019-12-31 0001580149 bivi:StockOptionNineMember 2019-07-01 2019-12-31 0001580149 us-gaap:WarrantMember 2019-12-31 0001580149 us-gaap:WarrantMember 2019-06-30 0001580149 2019-06-30 0001580149 us-gaap:CommonStockMember 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-12-31 0001580149 2018-12-31 0001580149 bivi:StockOptionTenMember 2019-12-31 0001580149 bivi:StockOptionTenMember 2019-07-01 2019-12-31 0001580149 2018-06-30 0001580149 us-gaap:CommonStockMember 2018-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001580149 us-gaap:RetainedEarningsMember 2018-06-30 0001580149 us-gaap:StockOptionMember 2018-07-01 2018-12-31 0001580149 us-gaap:WarrantMember 2018-07-01 2018-12-31 0001580149 bivi:DerivativeLiabilityWarrantsMember 2019-12-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2019-12-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001580149 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0001580149 2019-10-01 2019-12-31 0001580149 2018-10-01 2018-12-31 0001580149 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001580149 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001580149 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001580149 us-gaap:CommonStockMember 2019-09-30 0001580149 us-gaap:CommonStockMember 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-09-30 0001580149 2019-07-01 2019-09-30 0001580149 2018-07-01 2018-09-30 0001580149 2019-09-30 0001580149 2018-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-07-01 2019-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-10-01 2019-12-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-07-01 2019-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-10-01 2019-12-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

553918

674073

2339544

2574387

1085177

443480

4383972

443480

19472373

9392573

-2044428

2130907

2339544

2574387

10000000

800000000

5183724

4058724

-866815

-1211017

530000

2795700

518

406

0.001

5183724

4058724

641697

-456422

-336815

1584683

3108

339923

1630483

45800

0.0001

-21517319

-7262072

1439915

1554603

345711

1785626

1900314

114689

57344

688015

400540

346514

206019

613961

477069

306589

237507

1416665

992298

710447

500870

-1416665

-992298

-710447

-500870

3498535

271

20920

233

788

213

360

58000

5600

11200

25600

1600

4000

1600

4400

60400

800

1600

4000

12.50

3.75

6.25

7.5

8.75

12.5

26.25

12.29

27.5

28.75

31.25

5194924 BIOVIE INC. 0001580149 10-Q 2019-12-31 false --06-30 Yes Non-accelerated Filer Q2 2020

2843811

-940381

6665038

-500510

-3821227

6665038

-439871

-500510

-3821227

-439871

17099058 48659

4058724

5183724

2520431

788026

5183724

2520431

-2044428

406

9392573

-7262072

518

19472373

-21517319

2130907

253

9298563

-5758166

3540650

111199

4880246

-4769126

518

253

19461211

9282278

-28182357

-5257656

-8720628

4024875

48659 -17099058 -48659 -17099058

1435067

1374667

60400

1775925

44400

1731525

1439915

1554603

853855

739167

2293770

5600

11200

25600

1600

4000

1600

4400

60400

800

1600

4000

P4Y1M6D

P4Y2M12D

P6Y2M12D

P4Y3M18D

P3Y1M6D

P2Y9M18D

P2Y3M18D

P5Y2M12D

P2Y2M12D

P2Y7M6D

P10M24D

124667

45.00

P4Y8M12D

1250000

4.00

P4Y8M12D

P5Y7M6D

3040000

3200000 1150135 1 1150134 1150135 224 2 -2 48659

1272

3200000 3200000 3200000 2133332 -3200000 171 -171 -2133332 1706666

11162

19697

11162

16285

11162

3412

16285

3412

12.29

-14255247

-989040

6665038

-500510

-4260476 -51917 -7375485 -360 true false

-244300

7804 17935

The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td></tr> <tr style="vertical-align: bottom"> <td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td> <td style="width: 33%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">60,400</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 9%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">44,400</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,731,525</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Total</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">1,435,067</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">1,775,925</td> <td style="padding-bottom: 4pt"> </td></tr> </table>

2400

7.42

1374667

7.72

87480

2100

139498

716653

550810

334150

-216660

2100

114689

229377

178341

NV 001-39015 Yes 21595 573200 2674000

51400

7758778

7396192

7530308 3497264

1125000

112

10068638

10068750

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 99%">Related Party Transactions</td></tr> </table>   Equity Transactions with Acuitas   On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holding, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board. The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us. Each share of Preferred Stock automatically converted into 100 shares of common stock (prior to reverse split) upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018. Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that: <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; padding-bottom: 10pt; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 10pt; text-align: justify">Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20px; padding-bottom: 10pt; text-align: right">-</td> <td style="width: 7px"> </td> <td style="padding-bottom: 10pt; text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20px; padding-bottom: 10pt; text-align: right">-</td> <td style="width: 7px"> </td> <td style="padding-bottom: 10pt; text-align: justify">Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.</td></tr> </table> Convertible Debenture Transaction with Acuitas   On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the “Debenture”) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.   The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended December 31, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $21,595 for the six-month period ended December 31, 2019.   The Company received partial draws of draw number two of the Debenture of $25,000 and $5,000 on December 5, 2019 and December 13, 2019 respectively.  Acuitas and the Company continue to discuss the need and timing for some or all of the remaining draws under the Agreement.  (See subsequent events).   Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering. Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; line-height: 115%">-</td> <td style="text-align: justify; line-height: 115%">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; line-height: 115%">-</td> <td style="text-align: justify; line-height: 115%">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; line-height: 115%">-</td> <td style="text-align: justify; line-height: 115%">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto. </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">7.</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 99%">Equity Transactions</td></tr> </table>   Stock Options The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Remaining Average Contractual Term</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2019</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">58,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">12.50</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.2</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">87,480</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,400</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.42</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.1</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at December 31, 2019</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td> <td style="padding-bottom: 4pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at December 31, 2019</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td> <td style="padding-bottom: 4pt"> </td></tr> </table>   The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">December 31 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">December 31 2018</td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%; padding-left: 5.4pt">Expected life of options (In years)</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">71.55</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">67.91</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">1.61</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2.98</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Dividend Yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> </table>   Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred. The Company recorded stock-based compensation expense of $0 and $11,162 for the three- and six- month periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended December 31, 2018, respectively. The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Contract Life</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">3.75</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5,600</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">4.1</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5,600</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,200</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">7.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">8.75</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">12.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">25.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.8</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">26.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,400</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,400</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">27.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">800</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">28.75</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">31.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.9</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td></tr> </table> Stock Warrants The following table summarizes the warrants activity during the six months ended December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Life (Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">124,667</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">45.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.6</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">716,653</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,250,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.7</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">7.72</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4.7</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,498</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,455 expire in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending June 30, 2025.   Offerings of Common Stock and Warrants   Issuance of Stock Options   On October 1, 2019, the Company issued stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the date of issuance. On October 13, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $7.50 at any time from date of issuance and expire in 5 years from the date of issuance. On November 10, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.

Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net income (loss) per Common Share Basic net income (loss) per common share is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December 31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted loss since their effect was considered anti-dilutive. The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td></tr> <tr style="vertical-align: bottom"> <td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td> <td style="width: 34%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">60,400</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">44,400</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,731,525</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Total</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">1,435,067</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">1,775,925</td> <td style="padding-bottom: 4pt"> </td></tr> </table>

Recent accounting pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements. In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%; padding-left: 5.4pt">Intellectual Property</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,293,770</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,293,770</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(853,855</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(739,167</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">1,439,915</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">1,554,603</td> <td style="padding-bottom: 4pt"> </td></tr> </table>

Estimated future amortization expense is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2020 (Remaining six months)</td> <td style="white-space: nowrap; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt"> $                         114,689 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2021</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Thereafter</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            178,341 </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="border-top: black 1.5pt solid; white-space: nowrap; border-bottom: black 4.5pt double; padding-right: 5.4pt; padding-left: 5.4pt"> $                      1,439,915 </td></tr> </table>

At December 31, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="15" style="text-align: center">Fair Value Measurements at</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Level 1</td> <td> </td> <td colspan="3" style="text-align: center">Level 2</td> <td> </td> <td colspan="3" style="text-align: center">Level 3</td> <td> </td> <td colspan="3" style="text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%; padding-left: 5.4pt">Derivative liability - Warrants</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,674,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,674,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">   Total derivatives</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">—  </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">—  </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td> <td style="padding-bottom: 4pt"> </td></tr> </table>

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Derivative liabilities - Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Derivative liability - Conversion Option on Convertible Debenture</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Beginning balance at July 1, 2019</td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%; padding-left: 5.4pt">Additions to level 3 liabilities</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8,367,012</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,638,966</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td> <td> </td> <td> </td> <td style="text-align: right">(257,288</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(105,298</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Balance at September 30, 2019</td> <td> </td> <td> </td> <td style="text-align: right">8,109,724</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,533,668</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Additions to level 3 liabilities</td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td> <td> </td> <td> </td> <td style="text-align: right">(5,435,724</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(1,960,468</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Balance at December 31, 2019</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">2,674,000</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">573,200</td> <td style="padding-bottom: 4pt"> </td></tr> </table>

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Remaining Average Contractual Term</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2019</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">58,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">12.50</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.2</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">87,480</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,400</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.42</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.1</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at December 31, 2019</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td> <td style="padding-bottom: 4pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at December 31, 2019</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td> <td style="padding-bottom: 4pt"> </td></tr> </table>   The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">December 31 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">December 31 2018</td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%; padding-left: 5.4pt">Expected life of options (In years)</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">71.55</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">67.91</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">1.61</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2.98</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Dividend Yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> </table>

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Contract Life</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">3.75</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5,600</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">4.1</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5,600</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">6.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,200</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">7.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">8.75</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">12.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">25.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.8</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">26.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,400</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,400</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">27.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">800</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">28.75</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,600</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>$</td> <td style="text-align: right">31.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.9</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,000</td> <td> </td></tr> </table>

Stock Warrants The following table summarizes the warrants activity during the six months ended December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Life (Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">124,667</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">45.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.6</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">716,653</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,250,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.7</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">—  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">7.72</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4.7</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">139,498</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

229377 P4Y1M6D

P4Y6M

3247200

573200

2674000

573200

2533668

8109724

-257288

-5435724

-105298

-1960468

8367012

2638966

30000

500000 false

-3.06

-0.40

1.29

-0.20

-3.06

-0.40

1.29

-0.20

4661183

2497457

5183724

2520429

4661183

2497457

5183724

2520429

EX-101.CAL 9 bivi-20191231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 bivi-20191231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 bivi-20191231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Capital in Excess of Par Value Accumulated Deficit Derivative Instrument [Axis] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Additional Paid-In Capital Warrant [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Concentration Risk Benchmark [Axis] Derivative liability - Warrants [Member] Derivative Liability - Conversion Option on Convertible Debenture [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Preferred Stock Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Incorporation, State or Country Code Entity File Number Entity Interactive Data Current Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Other Assets Total Current Assets OTHER ASSETS: Intangible Assets Goodwill Total Fixed Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts Payable and accrued expenses Derivative liability - warrants Derivative liability - conversion option on convertible debenture Loan payable - related party Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively Total Current Liabilities Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2019 and June 30, 2019, respectively; 5,183,724 and 4,058,724 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively Additional paid in capital Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock Shares Issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Amortization Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Change in fair value of derivative liabilities Gain on settlement of debt Interest Expense Interest income TOTAL OTHER EXPENSE (INCOME) NET INCOME (LOSS) Deemed dividend NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS NET LOSS PER COMMON SHARE, BASIC NET LOSS PER COMMON SHARE, DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash to cash used by operating activities: Amortization of intangible assets Stock based compensation expense Gain on settlement of debt Interest expense from convertible debenture Changes in operating assets and liabilities: Other assets Accounts Payable Net cash used by operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of debt Proceeds from issuance of preferred shares Proceeds from loan payable - related party Proceeds from convertible debenture - related party Net cash provided by financing activities Net (decrease) increase in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for taxes NON-CASH INVESTING AND FINANCING ACTIVITIES Conversion of preferred shares to common stock Settlement of debt by issuance of common stock and forgiveness of debt Cashless exercise of warrants Deemed dividends for ratchet adjustments to warrants Deemed dividends for commitment shares Stock warrants classified as derivative liability Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance, Shares Issuance of shares in a private placement Issuance of shares in a private placement (in shares) Issuance of commitment shares Issuance of commitment shares, Shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock (in shares) Issuance of shares in exchange for debt settlement Issuance of shares in exchange for debt settlement, Shares Issuance of warrants in a private placement Issuance of warrants for services Stock option compensation Cashless exercise of warrants, Shares Deemed dividends for ratchet adjustment to warrants Net income (loss) Ending Balance Ending Balance, Shares Notes to Financial Statements Background Information Liquidity and Going Concern Accounting Policies [Abstract] Significant Accounting Policies Related Party Transactions [Abstract] Intangible Assets Related Party Transactions Fair Value Disclosures [Abstract] Fair Value Measurements Share-based Payment Arrangement [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation Net Loss per Common Share Recent accounting pronouncements Significant Accounting Policies Schedule of Dilutive securities were excluded from the computation of diluted loss per share Intangible Assets Schedule of Intangible Assets Schedule of Future expected Amortization of intangible assets Schedule of Estimated Fair Value of Derivative Liability Schedule of Liabilities Measured at Fair Value Equity Transactions Schedule of Stock Option Issued Schedule of option outstanding and exercisable by exercise price Schedule of Warrants Issued Dilutive Securities excluded from the Computation of Diluted Loss Per Share Intangible Assets Intellectual Property Accumulated Amortization Intellectual Property, Net Intangible Assets 2020 2021 2022 2023 2024 2025 Thereafter Total derivatives Beginning balance at July 1, 2019 Additions to level 3 liabilities EX-101.PRE 12 bivi-20191231_pre.xml XBRL PRESENTATION FILE EX-101.SCH 13 bivi-20191231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink XML 14 R28.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details 3) - Warrant [Member]	6 Months Ended
Equity Transactions (Details 3) - Warrant [Member]	Dec. 31, 2019 USD ($) $ / shares shares
Warrant Outstanding at the beginning of the year \| shares	124,667
Warrant Granted \| shares	1,250,000
Warrant Expired \| shares
Warrant Exercised \| shares	1,374,667
Weighted Average Exercise Price at the beginning of the year \| $ / shares	$ 45.00
Weighted Average Exercise Price, Granted \| $ / shares	4.00
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares	$ 7.72
Weighted Average Remaining Life at the beginning of the year	5 years 7 months 6 days
Weighted Average Remaining Life, Granted	4 years 8 months 12 days
Weighted Average Remaining Life at the end of year	4 years 8 months 12 days
Aggregate Intrinsic Value Outstanding at beginning of period \| $	$ 716,653
Aggregate Intrinsic Value Outstanding at end of period \| $	$ 139,498

ZIP 15 0001520138-20-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-20-000056-xbrl.zip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end XML 16 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements (Details) - USD ($)

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Total derivatives $ 3,247,200

Fair Value, Inputs, Level 3 [Member]

Total derivatives 573,200

Derivative liability - Warrants [Member]

Total derivatives 573,200

Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]

Total derivatives 2,674,000 $ 8,109,724

Derivative Liability - Conversion Option on Convertible Debenture [Member]

Total derivatives 2,674,000

Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]

Total derivatives $ 573,200 $ 2,533,668

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Equity Transactions (Tables)
6 Months Ended

Dec. 31, 2019

Disclosure Stock Options Tables Abstract

Schedule of Stock Option Issued
The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2019:

Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value

Outstanding at June 30, 2019 58,000 $ 12.50 5.2 $ 87,480

Granted 2,400 7.42 4.1 —

Options Exercised or Forfeited — — — —

Outstanding at December 31, 2019 60,400 $ 12.29 4.5 $ 2,100

Exercisable at December 31, 2019 60,400 $ 12.29 4.5 $ 2,100

The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019:

December 31 2019 December 31 2018

Expected life of options (In years) 5 5

Expected volatility 71.55 % 67.91 %

Risk free interest rate 1.61 % 2.98 %

Dividend Yield 0 % 0 %

Schedule of option outstanding and exercisable by exercise price
The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2019:

Exercise Price Outstanding Weighted Average Contract Life Exercisable

$ 3.75 5,600 4.1 5,600

$ 6.25 11,200 4.2 11,200

$ 7.50 25,600 6.2 25,600

$ 8.75 1,600 4.3 1,600

$ 12.50 4,000 3.1 4,000

$ 25.00 1,600 2.8 1,600

$ 26.25 4,400 2.3 4,400

$ 27.50 800 2.2 800

$ 28.75 1,600 2.6 1,600

$ 31.25 4,000 1.9 4,000

Schedule of Warrants Issued
Stock Warrants

The following table summarizes the warrants activity during the six months ended December 31, 2019:

Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value

Outstanding and exercisable at June 30, 2019 124,667 $ 45.00 5.6 $ 716,653

Granted 1,250,000 $ 4.00 4.7 $ —

Expired — $ — — $ —

Outstanding and exercisable at December 31, 2019 1,374,667 $ 7.72 4.7 $ 139,498

X

- References
No definition available.
+ Details

Name: bivi_DisclosureStockOptionsTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in common stock outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies (Policies)
6 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net Loss per Common Share
Net income (loss) per Common Share

Basic net income (loss) per common share is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding during the period.

Diluted net income (loss) per common share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December 31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018:

December 31, 2019 December 31, 2018

Number of Shares Number of Shares

Stock Options 60,400 44,400

Warrants 1,374,667 1,731,525

Total 1,435,067 1,775,925

Recent accounting pronouncements
Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)

Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Total

Beginning Balance at Jun. 30, 2018 $ 79 $ 4,880,246 $ (4,769,126) $ 111,199

Beginning Balance, Shares at Jun. 30, 2018 788,026

Issuance of shares in a private placement $ 3,200,000 3,200,000 3,200,000

Issuance of shares in a private placement (in shares) 2,133,332

Conversion of preferred stock to common stock $ (3,200,000) $ 171 (171)

Conversion of preferred stock to common stock (in shares) (2,133,332) 1,706,666

Issuance of shares in exchange for debt settlement $ 1 1,150,134 1,150,135

Issuance of shares in exchange for debt settlement, Shares 7,804

Stock option compensation 3,412 3,412

Cashless exercise of warrants $ 2 (2)

Cashless exercise of warrants, Shares 17,935

Deemed dividends for ratchet adjustment to warrants 48,659 (48,659)

Net income (loss) (439,871) (439,871)

Ending Balance at Sep. 30, 2018 $ 253 9,282,278 (5,257,656) 4,024,875

Ending Balance, Shares at Sep. 30, 2018 2,520,431

Beginning Balance at Jun. 30, 2018 $ 79 4,880,246 (4,769,126) 111,199

Beginning Balance, Shares at Jun. 30, 2018 788,026

Issuance of shares in exchange for debt settlement 1,150,135

Stock option compensation 19,697

Cashless exercise of warrants 224

Net income (loss) (940,381)

Ending Balance at Dec. 31, 2018 $ 253 9,298,563 (5,758,166) 3,540,650

Ending Balance, Shares at Dec. 31, 2018 2,520,431

Beginning Balance at Sep. 30, 2018 $ 253 9,282,278 (5,257,656) 4,024,875

Beginning Balance, Shares at Sep. 30, 2018 2,520,431

Stock option compensation 16,285 16,285

Net income (loss) (500,510) (500,510)

Ending Balance at Dec. 31, 2018 $ 253 9,298,563 (5,758,166) 3,540,650

Ending Balance, Shares at Dec. 31, 2018 2,520,431

Beginning Balance at Jun. 30, 2019 $ 406 9,392,573 (7,262,072) 2,130,907

Beginning Balance, Shares at Jun. 30, 2019 4,058,724

Issuance of commitment shares $ 112 10,068,638 10,068,750

Issuance of commitment shares, Shares 1,125,000

Deemed dividends for ratchet adjustment to warrants (17,099,058) (17,099,058)

Net income (loss) (3,821,227) (3,821,227)

Ending Balance at Sep. 30, 2019 $ 518 19,461,211 (28,182,357) (8,720,628)

Ending Balance, Shares at Sep. 30, 2019 5,183,724

Beginning Balance at Jun. 30, 2019 $ 406 9,392,573 (7,262,072) 2,130,907

Beginning Balance, Shares at Jun. 30, 2019 4,058,724

Issuance of shares in exchange for debt settlement

Stock option compensation 11,162

Cashless exercise of warrants

Net income (loss) 2,843,811

Ending Balance at Dec. 31, 2019 $ 518 19,472,373 (21,517,319) (2,044,428)

Ending Balance, Shares at Dec. 31, 2019 5,183,724

Beginning Balance at Sep. 30, 2019 $ 518 19,461,211 (28,182,357) (8,720,628)

Beginning Balance, Shares at Sep. 30, 2019 5,183,724

Stock option compensation 11,162 11,162

Net income (loss) 6,665,038 6,665,038

Ending Balance at Dec. 31, 2019 $ 518 $ 19,472,373 $ (21,517,319) $ (2,044,428)

Ending Balance, Shares at Dec. 31, 2019 5,183,724

X

- Definition
Cashless Exercise of Warrants.
+ References
No definition available.
+ Details

Name: bivi_CashlessExerciseOfWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cashless Exercise of Warrants Shares
+ References
No definition available.
+ Details

Name: bivi_CashlessExerciseOfWarrantsShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Conversion Of Preferred Stock To Common Stock.
+ References
No definition available.
+ Details

Name: bivi_ConversionOfPreferredStockToCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Conversion Of Preferred Stock To Common Stock (in shares)
+ References
No definition available.
+ Details

Name: bivi_ConversionOfPreferredStockToCommonStockInShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Deemed Dividends for Ratchet Adjustment to Warrant
+ References
No definition available.
+ Details

Name: bivi_DeemedDividendsForRatchetAdjustmentToWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance Of Preferred Stock In Private Placement
+ References
No definition available.
+ Details

Name: bivi_IssuanceOfPreferredStockInPrivatePlacement

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance Of Preferred Stock In Private Placement (in shares)
+ References
No definition available.
+ Details

Name: bivi_IssuanceOfPreferredStockInPrivatePlacementInShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Settlement Of Debt By Issuance Of Common Stock
+ References
No definition available.
+ Details

Name: bivi_SettlementOfDebtByIssuanceOfCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Settlement of Debt by Issuance of Common Stock, Shares
+ References
No definition available.
+ Details

Name: bivi_SettlementOfDebtByIssuanceOfCommonStockShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Balance Sheet (Unaudited) - USD ($)

Dec. 31, 2019

Jun. 30, 2019

CURRENT ASSETS:

Cash $ 3,108 $ 339,923

Other Assets 550,810 334,150

Total Current Assets 553,918 674,073

OTHER ASSETS:

Intangible Assets 1,439,915 1,554,603

Goodwill 345,711 345,711

Total Fixed Assets 1,785,626 1,900,314

TOTAL ASSETS 2,339,544 2,574,387

CURRENT LIABILITIES:

Accounts Payable and accrued expenses 1,085,177 443,480

Derivative liability - warrants 2,674,000

Derivative liability - conversion option on convertible debenture 573,200

Loan payable - related party 30,000

Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively 21,595

Total Current Liabilities 4,383,972 443,480

STOCKHOLDERS' EQUITY

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding

Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2019 and June 30, 2019, respectively; 5,183,724 and 4,058,724 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively 518 406

Additional paid in capital 19,472,373 9,392,573

Accumulated deficit (21,517,319) (7,262,072)

Total Stockholders' Equity (2,044,428) 2,130,907

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,339,544 $ 2,574,387

X

- Definition
Convertible debenture - related party
+ References
No definition available.
+ Details

Name: bivi_ConvertibleDebentureRelatedParty

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Derivative liability - conversion option on convertible debenture
+ References
No definition available.
+ Details

Name: bivi_DerivativeLiabilitiesConversionOptionCurrent

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Derivative liability - warrants
+ References
No definition available.
+ Details

Name: bivi_DerivativeLiabilitiesWarrantCurrent

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements
6 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

6. Fair Value Measurements

At December 31, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

Fair Value Measurements at

December 31, 2019

Level 1 Level 2 Level 3 Total

Derivative liability - Warrants $ — $ — $ 2,674,000 $ 2,674,000

Derivative liability -Conversion option on convertible debenture — — 573,200 573,200

 Total derivatives $ — $ — $ 3,247,200 $ 3,247,200

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2019:

Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019 $ — $ —

Additions to level 3 liabilities 8,367,012 2,638,966

Change in in fair value of level 3 liability (257,288 ) (105,298 )

Transfer in and/or out of Level 3 — —

Balance at September 30, 2019 8,109,724 2,533,668

Additions to level 3 liabilities — —

Change in in fair value of level 3 liability (5,435,724 ) (1,960,468 )

Transfer in and/or out of Level 3 — —

Balance at December 31, 2019 $ 2,674,000 $ 573,200

Derivative liability – Warrants

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise.

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions: stock price of $8.95, exercise price of $4.00, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of 0%, and risk-free interest rate of 1.52%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50, exercise price of $4.00, term of 5 year expiring September 2024, volatility of 80.79%, dividend yield of 0%, and risk-free interest rate of 1.69%. (See note 5 “Related Party Transactions – Convertible debenture transactions”)

Derivative liability – Conversion option in convertible debenture

The Company valued the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. (See note 5 “Related Party Transactions – Convertible debenture transactions with Acuitas” as of September 24, 2019). The conversion option was valued on September 24, 2019 using the Black Scholes-Mertons model with the following assumptions: stock price of $8.95, conversion price of $4.00, term of 1 year expiring September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50, conversion price of $4.00, term of 1 year expiring September 2020, volatility of 109.83%, dividend yield of 0%, and risk-free interest rate of 1.59%.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies (Tables)
6 Months Ended

Dec. 31, 2019

Disclosure Significant Accounting Policies Tables Abstract

Schedule of Dilutive securities were excluded from the computation of diluted loss per share
The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018:

December 31, 2019 December 31, 2018

Number of Shares Number of Shares

Stock Options 60,400 44,400

Warrants 1,374,667 1,731,525

Total 1,435,067 1,775,925

X

- References
No definition available.
+ Details

Name: bivi_DisclosureSignificantAccountingPoliciesTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Background Information
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Background Information

1. Background Information

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017. In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general agreement with the Company’s proposed randomized and controlled study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design. In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

X

- References
No definition available.
+ Details

Name: bivi_NotesToFinancialStatementsAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares

Dec. 31, 2019

Jun. 30, 2019

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 800,000,000 800,000,000

Common Stock Shares Issued 5,183,724 4,058,724

Common stock, shares outstanding 5,183,724 4,058,724

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Equity Transactions
6 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Equity Transactions

7. Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the six months ended December 31, 2019:

Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value

Outstanding at June 30, 2019 58,000 $ 12.50 5.2 $ 87,480

Granted 2,400 7.42 4.1 —

Options Exercised or Forfeited — — — —

Outstanding at December 31, 2019 60,400 $ 12.29 4.5 $ 2,100

Exercisable at December 31, 2019 60,400 $ 12.29 4.5 $ 2,100

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019:

December 31 2019 December 31 2018

Expected life of options (In years) 5 5

Expected volatility 71.55 % 67.91 %

Risk free interest rate 1.61 % 2.98 %

Dividend Yield 0 % 0 %

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $0 and $11,162 for the three- and six- month periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended December 31, 2018, respectively.

The following is a summary of stock options outstanding and exercisable by exercise price as of December 31, 2019:

Exercise Price Outstanding Weighted Average Contract Life Exercisable

$ 3.75 5,600 4.1 5,600

$ 6.25 11,200 4.2 11,200

$ 7.50 25,600 6.2 25,600

$ 8.75 1,600 4.3 1,600

$ 12.50 4,000 3.1 4,000

$ 25.00 1,600 2.8 1,600

$ 26.25 4,400 2.3 4,400

$ 27.50 800 2.2 800

$ 28.75 1,600 2.6 1,600

$ 31.25 4,000 1.9 4,000

Stock Warrants

The following table summarizes the warrants activity during the six months ended December 31, 2019:

Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value

Outstanding and exercisable at June 30, 2019 124,667 $ 45.00 5.6 $ 716,653

Granted 1,250,000 $ 4.00 4.7 $ —

Expired — $ — — $ —

Outstanding and exercisable at December 31, 2019 1,374,667 $ 7.72 4.7 $ 139,498

Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,455 expire in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending June 30, 2025.

Offerings of Common Stock and Warrants

Issuance of Stock Options

On October 1, 2019, the Company issued stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 13, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $7.50 at any time from date of issuance and expire in 5 years from the date of issuance.

On November 10, 2019, the Company issued stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 26 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ÐE>E @ <0H !@ !X;"]W;W)K^KF]6B_ES51E(_8JT;>ZYNKW5E3R ML4II^C[Q4EZNQDV0];+E%_%-F._M7MD1&:*WN]B)JG*1[#I^]4'30=,1Q\_O MT3_ZY&TR!Z[%3E8_RY.YKM)YFIS$F=\J\R(?GT2?T"1-^NR_B+NH+-RMQ&H< M9:7]-3G>M)%U'\4NI>9OW;UL_/W1O2F*GH836$]@ X&Q_Q+RGI /!.H52+0C45VU6NXV!7W.[<<\NDG_[?P[FZVVL_=UMB1W%Z9';#L$&R'H M@" V]B# ,($M W3VK\ .(G)<($RJ)IE>&S; MTT,4-=NC*;/FWIY,Y?[9V[K,6O=8'Z+F5)MLUP>51<09BZ,RRZMPM>C?/=:K MA3VW15Z9QSIHSF69U7_7IK"790CAVXOO^>'8=B^BU>*4'
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ÐE>E @ <0H M !@ ( !]@@ 'AL+W=O0, +P. 8 " =$+ !X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ PXM-4)#]6I9$! PA, !@ ( ! M]Q$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MPXM-4 UZDN6S 0 T@, !@ ( !=B$ 'AL+W=O*0 M>&PO=V]R:W-H965T&UL4$L! A0#% @ PXM-4%E5>1^S 0 T@, !D M ( !]BP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ PXM-4'C0FT[2 0 G 0 !D ( !MS( 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ PXM-4$;, ME/G' 0 -P0 !D ( !I#@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PXM-4+0NL\;L 0 ^@0 !D M ( !]SX 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ PXM-4&:[&LD& P , P !D ( ! MZT4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ PXM-4*10P4]T @ ;P@ !D ( !\$\ 'AL+W=OBP >&PO&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " ##BTU0&*.>G8(! #"$@ $P M@ $LDP 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 )0 E /4) #?E " ! end XML 28 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements (Details 2) - USD ($)
3 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Balance at September 30, 2019 $ 3,247,200

Fair Value, Inputs, Level 3 [Member]

Balance at September 30, 2019 573,200

Derivative liability - Warrants [Member]

Balance at September 30, 2019 573,200

Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]

Beginning balance at July 1, 2019 8,109,724

Additions to level 3 liabilities 8,367,012

Change in in fair value of level 3 liability (5,435,724) (257,288)

Transfer in and/or out of Level 3

Balance at September 30, 2019 2,674,000 8,109,724

Derivative Liability - Conversion Option on Convertible Debenture [Member]

Balance at September 30, 2019 2,674,000

Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]

Beginning balance at July 1, 2019 2,533,668

Additions to level 3 liabilities 2,638,966

Change in in fair value of level 3 liability (1,960,468) (105,298)

Transfer in and/or out of Level 3

Balance at September 30, 2019 $ 573,200 $ 2,533,668

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies (Details) - shares
6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 1,435,067 1,775,925

Warrant [Member]

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 1,374,667 1,731,525

Stock Option [Member]

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 60,400 44,400

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Significant Accounting Policies
6 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant Accounting Policies

Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net income (loss) per Common Share

Basic net income (loss) per common share is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding during the period.

Diluted net income (loss) per common share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December 31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

The table below shows the number of outstanding stock options and warrants as of December 31, 2019 and 2018:

December 31, 2019 December 31, 2018

Number of Shares Number of Shares

Stock Options 60,400 44,400

Warrants 1,374,667 1,731,525

Total 1,435,067 1,775,925



Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Fair Value Measurements (Tables)
6 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Schedule of Estimated Fair Value of Derivative Liability
At December 31, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

Fair Value Measurements at

December 31, 2019

Level 1 Level 2 Level 3 Total

Derivative liability - Warrants $ — $ — $ 2,674,000 $ 2,674,000

Derivative liability -Conversion option on convertible debenture — — 573,200 573,200

 Total derivatives $ — $ — $ 3,247,200 $ 3,247,200

Schedule of Liabilities Measured at Fair Value
The following table presents the activity for liabilities measured at fair value using unobservable inputs for the six months ended December 31, 2019:

Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019 $ — $ —

Additions to level 3 liabilities 8,367,012 2,638,966

Change in in fair value of level 3 liability (257,288 ) (105,298 )

Transfer in and/or out of Level 3 — —

Balance at September 30, 2019 8,109,724 2,533,668

Additions to level 3 liabilities — —

Change in in fair value of level 3 liability (5,435,724 ) (1,960,468 )

Transfer in and/or out of Level 3 — —

Balance at December 31, 2019 $ 2,674,000 $ 573,200

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative liabilities at fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Subsequent Events
6 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

9. Subsequent Events

On January 2, 2020, the Company issued 11,200 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $3.50.

On January 3, 2020, the Company received a third partial draw of $20,000 and on January 14, 2020 a fourth partial draw of $250,000 of draw number two of the Debenture. The total of the partial draw received under draw number two of the Debenture was $300,000 at February 12, 2020. Acuitas and the Company continue to discuss the need and timing for some or all the remaining draws under the Debenture Agreement.

On February 11, 2020, the Company entered into a letter agreement dated February 10, 2020 with Acuitas regarding Acuitas’ previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company’s intellectual property rights and commitment to purchase such securities upon the closing of the Company’s planned public offering (the “Public Offering”) of shares of Class A common stock (the “Common Stock”) as described in its Registration Statement on Form S-1 (File No. 333-231136) and commitment to purchase such additional securities would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company’s current bridge financing with Acuitas were to be made based with respect to the Company’s ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ 2,843,811 $ (940,381)

Adjustments to reconcile net loss to net cash to cash used by operating activities:

Amortization of intangible assets 114,689 114,689

Stock based compensation expense 11,162 19,697

Gain on settlement of debt 51,400

Interest expense from convertible debenture 3,497,264

Change in fair value of derivative liabilities (7,758,778)

Changes in operating assets and liabilities:

Other assets (216,660)

Accounts Payable 641,697 (456,422)

Net cash used by operating activities (866,815) (1,211,017)

CASH FLOWS FROM FINANCING ACTIVITIES:

Repayment of debt (244,300)

Proceeds from issuance of preferred shares 3,040,000

Proceeds from loan payable - related party 30,000

Proceeds from convertible debenture - related party 500,000

Net cash provided by financing activities 530,000 2,795,700

Net (decrease) increase in cash (336,815) 1,584,683

Cash, beginning of period 339,923 45,800

Cash, end of period 3,108 1,630,483

SUPPLEMENTAL CASH FLOW INFORMATION:

Cash paid for interest 1,272

Cash paid for taxes

NON-CASH INVESTING AND FINANCING ACTIVITIES

Conversion of preferred shares to common stock 3,200,000

Settlement of debt by issuance of common stock and forgiveness of debt 1,150,135

Cashless exercise of warrants 224

Deemed dividends for ratchet adjustments to warrants 48,659

Deemed dividends for commitment shares 17,099,058 48,659

Stock warrants classified as derivative liability $ 7,530,308

X

- Definition
Cashless Exercise of Warrants.
+ References
No definition available.
+ Details

Name: bivi_CashlessExerciseOfWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Conversion Of Preferred Shares To Common Stock.
+ References
No definition available.
+ Details

Name: bivi_ConversionOfPreferredSharesToCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Deemed Dividend
+ References
No definition available.
+ Details

Name: bivi_DeemedDividend

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Deemed Dividends for Ratchet Adjustments to Warrants.
+ References
No definition available.
+ Details

Name: bivi_DeemedDividendsForRatchetAdjustmentsToWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest expense from convertible debenture
+ References
No definition available.
+ Details

Name: bivi_InterestExpenseFromConvertibleDebenture

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds From Convertible Debenture Related Party
+ References
No definition available.
+ Details

Name: bivi_ProceedsFromConvertibleDebentureRelatedParty

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Settlement Of Debt By Issuance Of Common Stock
+ References
No definition available.
+ Details

Name: bivi_SettlementOfDebtByIssuanceOfCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Stock warrants classified as derivative liability
+ References
No definition available.
+ Details

Name: bivi_StockWarrantsClassifiedAsDerivativeLiability

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.13(h))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_GainLossOnSaleOfDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Document and Entity Information - shares
6 Months Ended

Dec. 31, 2019

Feb. 05, 2020

Document And Entity Information

Entity Registrant Name BIOVIE INC.

Entity Central Index Key 0001580149

Document Type 10-Q

Document Period End Date Dec. 31, 2019

Amendment Flag false

Current Fiscal Year End Date --06-30

Is Entity's Reporting Status Current? Yes

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 5,194,924

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2020

Entity Shell Company false

Entity Emerging Growth Company false

Entity Small Business true

Entity Incorporation, State or Country Code NV

Entity File Number 001-39015

Entity Interactive Data Current Yes

X

- References
No definition available.
+ Details

Name: bivi_DocumentAndEntityInformationAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 35 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Related Party Transactions
6 Months Ended

Dec. 31, 2019

Related Party Transactions [Abstract]

Related Party Transactions

5. Related Party Transactions

Equity Transactions with Acuitas

On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holding, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us.

Each share of Preferred Stock automatically converted into 100 shares of common stock (prior to reverse split) upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

- Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock;

- Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;

- Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

Convertible Debenture Transaction with Acuitas

On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the “Debenture”) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.

The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended December 31, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $21,595 for the six-month period ended December 31, 2019.

The Company received partial draws of draw number two of the Debenture of $25,000 and $5,000 on December 5, 2019 and December 13,2019 respectively. Acuitas and the Company continue to discuss the need and timing for some or all of the remaining draws under the Agreement. (See subsequent events).

Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

- The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

- Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

- The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 85 232 1 false 19 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nanoantibiotics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheet (Unaudited) Sheet http://nanoantibiotics.com/role/BalanceSheet Condensed Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetParenthetical Condensed Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity and Going Concern Sheet http://nanoantibiotics.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://nanoantibiotics.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://nanoantibiotics.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://nanoantibiotics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Equity Transactions Sheet http://nanoantibiotics.com/role/EquityTransactions Equity Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://nanoantibiotics.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://nanoantibiotics.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Intangible Assets (Tables) Sheet http://nanoantibiotics.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://nanoantibiotics.com/role/IntangibleAssets 18 false false R19.htm 00000019 - Disclosure - Fair Value Measurements (Tables) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://nanoantibiotics.com/role/FairValueMeasurements 19 false false R20.htm 00000020 - Disclosure - Equity Transactions (Tables) Sheet http://nanoantibiotics.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://nanoantibiotics.com/role/EquityTransactions 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies (Details) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Details) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Details 2) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails2 Intangible Assets (Details 2) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurements (Details) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements (Details 2) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 25 false false R26.htm 00000026 - Disclosure - Equity Transactions (Details) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://nanoantibiotics.com/role/EquityTransactionsTables 26 false false R27.htm 00000027 - Disclosure - Equity Transactions (Details 2) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://nanoantibiotics.com/role/EquityTransactionsTables 27 false false R28.htm 00000028 - Disclosure - Equity Transactions (Details 3) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails3 Equity Transactions (Details 3) Details http://nanoantibiotics.com/role/EquityTransactionsTables 28 false false All Reports Book All Reports bivi-20191231.xml bivi-20191231.xsd bivi-20191231_cal.xml bivi-20191231_def.xml bivi-20191231_lab.xml bivi-20191231_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 37 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Equity Transactions (Details 2) - Stock Option [Member]
6 Months Ended

Dec. 31, 2019

$ / shares

shares

Exercise Price | $ / shares $ 3.75

Option Outstanding 5,600

Weighted Average Contractual Life 4 years 1 month 6 days

Option Excersiable 5,600

Exercise Price | $ / shares $ 6.25

Option Outstanding 11,200

Weighted Average Contractual Life 4 years 2 months 12 days

Option Excersiable 11,200

Exercise Price | $ / shares $ 7.5

Option Outstanding 25,600

Weighted Average Contractual Life 6 years 2 months 12 days

Option Excersiable 25,600

Exercise Price | $ / shares $ 8.75

Option Outstanding 1,600

Weighted Average Contractual Life 4 years 3 months 18 days

Option Excersiable 1,600

Exercise Price | $ / shares $ 12.5

Option Outstanding 4,000

Weighted Average Contractual Life 3 years 1 month 6 days

Option Excersiable 4,000

Exercise Price | $ / shares $ 25

Option Outstanding 1,600

Weighted Average Contractual Life 2 years 9 months 18 days

Option Excersiable 1,600

Exercise Price | $ / shares $ 26.25

Option Outstanding 4,400

Weighted Average Contractual Life 2 years 3 months 18 days

Option Excersiable 4,400

Exercise Price | $ / shares $ 27.5

Option Outstanding 800

Weighted Average Contractual Life 2 years 2 months 12 days

Option Excersiable 800

Exercise Price | $ / shares $ 28.75

Option Outstanding 1,600

Weighted Average Contractual Life 2 years 7 months 6 days

Option Excersiable 1,600

Exercise Price | $ / shares $ 31.25

Option Outstanding 4,000

Weighted Average Contractual Life 10 months 24 days

Option Excersiable 4,000

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets (Details 2) - USD ($)

Dec. 31, 2019

Jun. 30, 2019

Disclosure Intangible Assets Details 2Abstract

2020 $ 114,689

2021 229,377

2022 229,377

2023 229,377

2024 229,377

2025 229,377

Thereafter 178,341

Intellectual Property, Net $ 1,439,915 $ 1,554,603

X

- References
No definition available.
+ Details

Name: bivi_DisclosureIntangibleAssetsDetails2Abstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the sixth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Equity Transactions (Details) - Stock Option [Member]
6 Months Ended

Dec. 31, 2019

USD ($)

$ / shares

shares

Option Outstanding at beginning of period | shares 58,000

Option Granted | shares 2,400

Option Exercised | shares

Option Outstanding at end of period | shares 60,400

Option Excersiable at end of period | shares 60,400

Outstanding Weighted Average Exercise Price at the beginning of period | $ / shares $ 12.50

Weighted Average Exercise Price, Granted | $ / shares 7.42

Weighted Average Exercise Price, Exercised | $ / shares

Outstanding Weighted Average Exercise Price at the end of period | $ / shares 12.29

Excersiable Weighted Average Exercise Price at the end of period | $ / shares $ 12.29

Weighted Average Remaining Contractual Term at the beginning of period 5 years 2 months 12 days

Weighted Average Remaining Contractual Term at the end 4 years 1 month 6 days

Excersiable Weighted Average Remaining Contractual Term at the end of period 4 years 6 months

Aggregate Intrinsic Value Outstanding at beginning of period | $ $ 87,480

Granted | $

Options Exercised or Forfeited | $

Aggregate Intrinsic Value Outstanding at end of period | $ 2,100

Aggregate Intrinsic Value Exercisable | $ $ 2,100

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4

Namespace Prefix: bivi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets (Details) - USD ($)

Dec. 31, 2019

Jun. 30, 2019

Disclosure Intangible Assets Details Abstract

Intellectual Property $ 2,293,770 $ 2,293,770

Accumulated Amortization (853,855) (739,167)

Intellectual Property, Net $ 1,439,915 $ 1,554,603

X

- References
No definition available.
+ Details

Name: bivi_DisclosureIntangibleAssetsDetailsAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 43 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Commitments and Contingencies
6 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

Office Lease

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country.

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally the Company obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy).

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

OPERATING EXPENSES

Amortization $ 57,344 $ 57,344 $ 114,689 $ 114,689

Research and development expenses 346,514 206,019 688,015 400,540

Selling, general and administrative expenses 306,589 237,507 613,961 477,069

TOTAL OPERATING EXPENSES 710,447 500,870 1,416,665 992,298

LOSS FROM OPERATIONS (710,447) (500,870) (1,416,665) (992,298)

OTHER EXPENSE (INCOME)

Change in fair value of derivative liabilities (7,396,192) (7,758,778)

Gain on settlement of debt (51,400)

Interest Expense 20,920 3,498,535 271

Interest income (213) (360) (233) (788)

TOTAL OTHER EXPENSE (INCOME) (7,375,485) (360) (4,260,476) (51,917)

NET INCOME (LOSS) 6,665,038 (500,510) 2,843,811 (940,381)

Deemed dividend 17,099,058 48,659

NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS $ 6,665,038 $ (500,510) $ (14,255,247) $ (989,040)

NET LOSS PER COMMON SHARE, BASIC $ 1.29 $ (0.20) $ (3.06) $ (0.40)

NET LOSS PER COMMON SHARE, DILUTED $ 1.29 $ (0.20) $ (3.06) $ (0.40)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC 5,183,724 2,520,429 4,661,183 2,497,457

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED 5,183,724 2,520,429 4,661,183 2,497,457

X

- Definition
Deemed Dividend
+ References
No definition available.
+ Details

Name: bivi_DeemedDividend

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total Other Expense Income.
+ References
No definition available.
+ Details

Name: bivi_TotalOtherExpenseIncome

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.13(h))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_GainLossOnSaleOfDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.20)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest income earned from interest bearing assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets
6 Months Ended

Dec. 31, 2019

Related Party Transactions [Abstract]

Intangible Assets

4. Intangible Assets

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:

December 31, 2019 June 30, 2019

Intellectual Property $ 2,293,770 $ 2,293,770

Less Accumulated Amortization (853,855 ) (739,167 )

Intellectual Property, Net $ 1,439,915 $ 1,554,603

Amortization expense for the three-month period ended December 31, 2019 and 2018 was $57,344 and $57,344 respectively Amortization expense for the six-month period ended December 31, 2019 and 2018 was $114,689 and $114,689 respectively.

Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining six months) $ 114,689

2021 229,377

2022 229,377

2023 229,377

2024 229,377

2025 229,377

Thereafter 178,341

$ 1,439,915

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Liquidity and Going Concern
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Liquidity and Going Concern

2. Liquidity and Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company had an accumulated deficit of approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of December 31, 2019. In December 2019, Acuitas provided the Company, a short-term interest free advance of $30,000. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b/3 clinical trial until sufficient funding is secured.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected the reverse stock split of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

X

- Definition
Liquidity [Text Block]
+ References
No definition available.
+ Details

Name: bivi_LiquidityTextBlock

Namespace Prefix: bivi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: bivi_NotesToFinancialStatementsAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets (Tables)
6 Months Ended

Dec. 31, 2019

Disclosure Intangible Assets Tables Abstract

Schedule of Intangible Assets
The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:

December 31, 2019 June 30, 2019

Intellectual Property $ 2,293,770 $ 2,293,770

Less Accumulated Amortization (853,855 ) (739,167 )

Intellectual Property, Net $ 1,439,915 $ 1,554,603

Schedule of Future expected Amortization of intangible assets
Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining six months) $ 114,689

2021 229,377

2022 229,377

2023 229,377

2024 229,377

2025 229,377

Thereafter 178,341

$ 1,439,915

X

- References
No definition available.
+ Details

Name: bivi_DisclosureIntangibleAssetsTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2019	Sep. 30, 2019
Total derivatives	$ 3,247,200
Fair Value, Inputs, Level 3 [Member]
Total derivatives	573,200
Derivative liability - Warrants [Member]
Total derivatives	573,200
Derivative liability - Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Total derivatives	2,674,000	$ 8,109,724
Derivative Liability - Conversion Option on Convertible Debenture [Member]
Total derivatives	2,674,000
Derivative Liability - Conversion Option on Convertible Debenture [Member] \| Fair Value, Inputs, Level 3 [Member]
Total derivatives	$ 573,200	$ 2,533,668

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2018		$ 79	$ 4,880,246	$ (4,769,126)	$ 111,199
Beginning Balance, Shares at Jun. 30, 2018		788,026
Issuance of shares in a private placement	$ 3,200,000		3,200,000		3,200,000
Issuance of shares in a private placement (in shares)	2,133,332
Conversion of preferred stock to common stock	$ (3,200,000)	$ 171	(171)
Conversion of preferred stock to common stock (in shares)	(2,133,332)	1,706,666
Issuance of shares in exchange for debt settlement		$ 1	1,150,134		1,150,135
Issuance of shares in exchange for debt settlement, Shares		7,804
Stock option compensation			3,412		3,412
Cashless exercise of warrants		$ 2	(2)
Cashless exercise of warrants, Shares		17,935
Deemed dividends for ratchet adjustment to warrants			48,659	(48,659)
Net income (loss)				(439,871)	(439,871)
Ending Balance at Sep. 30, 2018		$ 253	9,282,278	(5,257,656)	4,024,875
Ending Balance, Shares at Sep. 30, 2018		2,520,431
Beginning Balance at Jun. 30, 2018		$ 79	4,880,246	(4,769,126)	111,199
Beginning Balance, Shares at Jun. 30, 2018		788,026
Issuance of shares in exchange for debt settlement					1,150,135
Stock option compensation					19,697
Cashless exercise of warrants					224
Net income (loss)					(940,381)
Ending Balance at Dec. 31, 2018		$ 253	9,298,563	(5,758,166)	3,540,650
Ending Balance, Shares at Dec. 31, 2018		2,520,431
Beginning Balance at Sep. 30, 2018		$ 253	9,282,278	(5,257,656)	4,024,875
Beginning Balance, Shares at Sep. 30, 2018		2,520,431
Stock option compensation			16,285		16,285
Net income (loss)				(500,510)	(500,510)
Ending Balance at Dec. 31, 2018		$ 253	9,298,563	(5,758,166)	3,540,650
Ending Balance, Shares at Dec. 31, 2018		2,520,431
Beginning Balance at Jun. 30, 2019		$ 406	9,392,573	(7,262,072)	2,130,907
Beginning Balance, Shares at Jun. 30, 2019		4,058,724
Issuance of commitment shares		$ 112	10,068,638		10,068,750
Issuance of commitment shares, Shares		1,125,000
Deemed dividends for ratchet adjustment to warrants				(17,099,058)	(17,099,058)
Net income (loss)				(3,821,227)	(3,821,227)
Ending Balance at Sep. 30, 2019		$ 518	19,461,211	(28,182,357)	(8,720,628)
Ending Balance, Shares at Sep. 30, 2019		5,183,724
Beginning Balance at Jun. 30, 2019		$ 406	9,392,573	(7,262,072)	2,130,907
Beginning Balance, Shares at Jun. 30, 2019		4,058,724
Issuance of shares in exchange for debt settlement
Stock option compensation					11,162
Cashless exercise of warrants
Net income (loss)					2,843,811
Ending Balance at Dec. 31, 2019		$ 518	19,472,373	(21,517,319)	(2,044,428)
Ending Balance, Shares at Dec. 31, 2019		5,183,724
Beginning Balance at Sep. 30, 2019		$ 518	19,461,211	(28,182,357)	(8,720,628)
Beginning Balance, Shares at Sep. 30, 2019		5,183,724
Stock option compensation			11,162		11,162
Net income (loss)				6,665,038	6,665,038
Ending Balance at Dec. 31, 2019		$ 518	$ 19,472,373	$ (21,517,319)	$ (2,044,428)
Ending Balance, Shares at Dec. 31, 2019		5,183,724

Condensed Balance Sheet (Unaudited) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
CURRENT ASSETS:
Cash	$ 3,108	$ 339,923
Other Assets	550,810	334,150
Total Current Assets	553,918	674,073
OTHER ASSETS:
Intangible Assets	1,439,915	1,554,603
Goodwill	345,711	345,711
Total Fixed Assets	1,785,626	1,900,314
TOTAL ASSETS	2,339,544	2,574,387
CURRENT LIABILITIES:
Accounts Payable and accrued expenses	1,085,177	443,480
Derivative liability - warrants	2,674,000
Derivative liability - conversion option on convertible debenture	573,200
Loan payable - related party	30,000
Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively	21,595
Total Current Liabilities	4,383,972	443,480
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2019 and June 30, 2019, respectively; 5,183,724 and 4,058,724 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively	518	406
Additional paid in capital	19,472,373	9,392,573
Accumulated deficit	(21,517,319)	(7,262,072)
Total Stockholders' Equity	(2,044,428)	2,130,907
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,339,544	$ 2,574,387

Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common Stock Shares Issued	5,183,724	4,058,724
Common stock, shares outstanding	5,183,724	4,058,724

Fair Value Measurements (Details 2) - USD ($)	3 Months Ended
Fair Value Measurements (Details 2) - USD ($)	Dec. 31, 2019	Sep. 30, 2019
Balance at September 30, 2019	$ 3,247,200
Fair Value, Inputs, Level 3 [Member]
Balance at September 30, 2019	573,200
Derivative liability - Warrants [Member]
Balance at September 30, 2019	573,200
Derivative liability - Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Beginning balance at July 1, 2019	8,109,724
Additions to level 3 liabilities		8,367,012
Change in in fair value of level 3 liability	(5,435,724)	(257,288)
Transfer in and/or out of Level 3
Balance at September 30, 2019	2,674,000	8,109,724
Derivative Liability - Conversion Option on Convertible Debenture [Member]
Balance at September 30, 2019	2,674,000
Derivative Liability - Conversion Option on Convertible Debenture [Member] \| Fair Value, Inputs, Level 3 [Member]
Beginning balance at July 1, 2019	2,533,668
Additions to level 3 liabilities		2,638,966
Change in in fair value of level 3 liability	(1,960,468)	(105,298)
Transfer in and/or out of Level 3
Balance at September 30, 2019	$ 573,200	$ 2,533,668

Significant Accounting Policies (Details) - shares	6 Months Ended
Significant Accounting Policies (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	1,435,067	1,775,925
Warrant [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	1,374,667	1,731,525
Stock Option [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	60,400	44,400

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ 2,843,811	$ (940,381)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Amortization of intangible assets	114,689	114,689
Stock based compensation expense	11,162	19,697
Gain on settlement of debt		51,400
Interest expense from convertible debenture	3,497,264
Change in fair value of derivative liabilities	(7,758,778)
Changes in operating assets and liabilities:
Other assets	(216,660)
Accounts Payable	641,697	(456,422)
Net cash used by operating activities	(866,815)	(1,211,017)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt		(244,300)
Proceeds from issuance of preferred shares		3,040,000
Proceeds from loan payable - related party	30,000
Proceeds from convertible debenture - related party	500,000
Net cash provided by financing activities	530,000	2,795,700
Net (decrease) increase in cash	(336,815)	1,584,683
Cash, beginning of period	339,923	45,800
Cash, end of period	3,108	1,630,483
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	1,272
Cash paid for taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of preferred shares to common stock		3,200,000
Settlement of debt by issuance of common stock and forgiveness of debt		1,150,135
Cashless exercise of warrants		224
Deemed dividends for ratchet adjustments to warrants		48,659
Deemed dividends for commitment shares	17,099,058	48,659
Stock warrants classified as derivative liability	$ 7,530,308

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2019	Feb. 05, 2020
Document And Entity Information
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		5,194,924
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Incorporation, State or Country Code	NV
Entity File Number	001-39015
Entity Interactive Data Current	Yes

Equity Transactions (Details 2) - Stock Option [Member]	6 Months Ended
Equity Transactions (Details 2) - Stock Option [Member]	Dec. 31, 2019 $ / shares shares
Exercise Price \| $ / shares	$ 3.75
Option Outstanding	5,600
Weighted Average Contractual Life	4 years 1 month 6 days
Option Excersiable	5,600
Exercise Price \| $ / shares	$ 6.25
Option Outstanding	11,200
Weighted Average Contractual Life	4 years 2 months 12 days
Option Excersiable	11,200
Exercise Price \| $ / shares	$ 7.5
Option Outstanding	25,600
Weighted Average Contractual Life	6 years 2 months 12 days
Option Excersiable	25,600
Exercise Price \| $ / shares	$ 8.75
Option Outstanding	1,600
Weighted Average Contractual Life	4 years 3 months 18 days
Option Excersiable	1,600
Exercise Price \| $ / shares	$ 12.5
Option Outstanding	4,000
Weighted Average Contractual Life	3 years 1 month 6 days
Option Excersiable	4,000
Exercise Price \| $ / shares	$ 25
Option Outstanding	1,600
Weighted Average Contractual Life	2 years 9 months 18 days
Option Excersiable	1,600
Exercise Price \| $ / shares	$ 26.25
Option Outstanding	4,400
Weighted Average Contractual Life	2 years 3 months 18 days
Option Excersiable	4,400
Exercise Price \| $ / shares	$ 27.5
Option Outstanding	800
Weighted Average Contractual Life	2 years 2 months 12 days
Option Excersiable	800
Exercise Price \| $ / shares	$ 28.75
Option Outstanding	1,600
Weighted Average Contractual Life	2 years 7 months 6 days
Option Excersiable	1,600
Exercise Price \| $ / shares	$ 31.25
Option Outstanding	4,000
Weighted Average Contractual Life	10 months 24 days
Option Excersiable	4,000

Intangible Assets (Details 2) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Disclosure Intangible Assets Details 2Abstract
2020	$ 114,689
2021	229,377
2022	229,377
2023	229,377
2024	229,377
2025	229,377
Thereafter	178,341
Intellectual Property, Net	$ 1,439,915	$ 1,554,603

Equity Transactions (Details) - Stock Option [Member]	6 Months Ended
Equity Transactions (Details) - Stock Option [Member]	Dec. 31, 2019 USD ($) $ / shares shares
Option Outstanding at beginning of period \| shares	58,000
Option Granted \| shares	2,400
Option Exercised \| shares
Option Outstanding at end of period \| shares	60,400
Option Excersiable at end of period \| shares	60,400
Outstanding Weighted Average Exercise Price at the beginning of period \| $ / shares	$ 12.50
Weighted Average Exercise Price, Granted \| $ / shares	7.42
Weighted Average Exercise Price, Exercised \| $ / shares
Outstanding Weighted Average Exercise Price at the end of period \| $ / shares	12.29
Excersiable Weighted Average Exercise Price at the end of period \| $ / shares	$ 12.29
Weighted Average Remaining Contractual Term at the beginning of period	5 years 2 months 12 days
Weighted Average Remaining Contractual Term at the end	4 years 1 month 6 days
Excersiable Weighted Average Remaining Contractual Term at the end of period	4 years 6 months
Aggregate Intrinsic Value Outstanding at beginning of period \| $	$ 87,480
Granted \| $
Options Exercised or Forfeited \| $
Aggregate Intrinsic Value Outstanding at end of period \| $	2,100
Aggregate Intrinsic Value Exercisable \| $	$ 2,100

Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Disclosure Intangible Assets Details Abstract
Intellectual Property	$ 2,293,770	$ 2,293,770
Accumulated Amortization	(853,855)	(739,167)
Intellectual Property, Net	$ 1,439,915	$ 1,554,603